A Phase 2 Study of BIT225, a Human Immunodeficiency Virus-1 (HIV-1) Vpu Inhibitor, in Treatment Naive HIV-1 Infected Individuals Commencing Dolutegravir-based Combination Antiretroviral Therapy (cART): Evaluation of Safety, Efficacy and Inflammatory and Immune Activation Markers.
Latest Information Update: 16 Aug 2023
At a glance
- Drugs BIT 225 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors Biotron
- 28 Jul 2023 According to Biotron media release ,preliminary results from this study anticipated in the third quarter of 2023.
- 23 Jul 2021 New trial record